LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of IMUNON's management team will also be conducting in-person one-on-one meetings with investors September 8 - 10, 2025. H.C. Wain ...

Core Insights - IMUNON, Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring uninterrupted trading on The Nasdaq Capital Market [1][2] - The company recently issued a 15% stock dividend to shareholders, reflecting confidence in its clinical pipeline and commitment to investors [2] - IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, with positive results from the Phase 2 OVATION 2 trial [2][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [3] - The company is developing non-viral DNA technology, with its first modality, TheraPlas, aimed at gene-based delivery of therapeutic proteins for solid tumors [3] - The second modality, PlaCCine, is designed for gene delivery of viral antigens to elicit strong immunological responses [3] Clinical Development - IMNN-001 instructs the body to produce cancer-fighting molecules at the tumor site and has completed multiple clinical trials, including the Phase 2 OVATION 2 trial [4] - IMUNON has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101 [4] - The company aims to advance its technological capabilities in plasmid DNA to better address difficult-to-treat conditions [4]

The following is a summary of remarks by Imunon's President and CEO Stacy Lindborg, PhD. on the second quarter 2025 financial results conference call, provided for Shareholders unable to join the call: Advancing the Pivotal Phase 3 OVATION 3 Trial for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer: The Company is well-positioned for efficient and timely execution of this pivotal Phase 3 study, and has enrolled and begun treating its first patient on the protocol, building on the robust Phase 2 OVATION ...

Imunon (IMNN) Q2 2025 Earnings Call August 05, 2025 11:00 AM ET Speaker0Good morning. My name is Dovan, and I will be your operator today. At this time, I would like to welcome you to ImmuNon's Second Quarter twenty twenty five Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers' prepared remarks, there will be a question and answer session.I would now like to turn the call over to Peter Voso of ICR Healthcare Investor Relations repre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (Former ...

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET Exhibit 99.1 LAWRENCEVILLE, N.J., August 5, 2025 – IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported fin ...

Core Viewpoint - IMUNON, Inc. has initiated the pivotal Phase 3 OVATION 3 Study for its lead candidate IMNN-001, aimed at treating newly diagnosed advanced ovarian cancer, with the first patient dosed [1][2]. Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms for effective disease responses [8]. - The company is advancing its non-viral DNA technology, with its first modality, TheraPlas, designed for gene-based delivery of cytokines in solid tumors [8][9]. Product Development - IMNN-001 is a DNA-mediated immunotherapy that has shown significant therapeutic potential in previous clinical trials, including improvements in overall survival and progression-free survival [2][3]. - The Phase 3 OVATION 3 trial will assess IMNN-001 in combination with standard chemotherapy, targeting women with advanced ovarian cancer [1][4]. Clinical Trial Details - The OVATION 3 trial will randomize participants 1:1 to receive either IMNN-001 plus neoadjuvant/adjuvant chemotherapy or standard chemotherapy alone, focusing on overall survival as the primary endpoint [1][4]. - The Phase 2 OVATION 2 Study demonstrated consistent improvements in key endpoints, including overall survival and safety profile, with 112 patients enrolled [3][4]. Mechanism of Action - IMNN-001 utilizes a proprietary TheraPlas platform to deliver IL-12, a potent cytokine that induces strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation [6][9]. - Recent data indicates that IMNN-001 creates a "hot" anti-tumor microenvironment by recruiting immune cells to the tumor site, enhancing its therapeutic efficacy [3][6]. Market Context - Epithelial ovarian cancer is a significant health concern, with approximately 20,000 new cases annually in the U.S., and a high percentage diagnosed at advanced stages [7]. - The need for effective therapies is critical, as current options primarily include chemotherapy and surgery, with poor five-year survival rates for advanced stages [7].

Core Viewpoint - IMUNON, Inc. is set to host a conference call on August 5, 2025, to discuss its Q2 2025 financial results and provide updates on its clinical development program, particularly focusing on the Phase 3 trial of its DNA-based immunotherapy, IMNN-001, for advanced ovarian cancer [1]. Company Overview - IMUNON is a clinical-stage biotechnology company that develops innovative treatments utilizing the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4]. - The company is advancing its non-viral DNA technology through two main modalities: TheraPlas® for gene-based delivery of cytokines and PlaCCine® for gene delivery of viral antigens [4]. Clinical Development - The lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, which has completed multiple trials, including a Phase 2 trial (OVATION 2) [5]. - The first site for the Phase 3 pivotal study (OVATION 3) was initiated in Q2 2025, with IMNN-001 designed to instruct the body to produce cancer-fighting molecules at the tumor site [5]. - Additionally, the company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101) [5].

Core Viewpoint - IMUNON, Inc. announced a 15% stock dividend, reflecting the company's confidence in its Phase 3 clinical study and long-term growth potential, while also demonstrating dedication to its shareholders [1][3]. Group 1: Stock Dividend Details - The stock dividend program will distribute approximately 448,000 additional shares of IMUNON common stock for each share held, payable to holders of record as of August 7, 2025, with distribution expected on August 21, 2025 [2]. - Stockholders will not need to take any action to receive the dividend, as additional shares will be credited to their accounts [2]. Group 2: Company Strategy and Clinical Programs - The stock dividend is a way for the company to share its recent clinical progress and optimism with shareholders, emphasizing its commitment to creating value while advancing its innovative pipeline of therapies [3]. - IMUNON is focused on developing transformative treatments, including its lead program IMNN-001 for advanced ovarian cancer, which has shown promising Phase 2 clinical data and is currently in a Phase 3 pivotal trial [3][5]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company that develops innovative treatments utilizing non-viral DNA technology, with a focus on solid tumors and immunological responses [4]. - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, instructing the body to produce cancer-fighting molecules at the tumor site [5].